Drug intelligence / Profile preview

PDA001

Development stage: Phase 2
Lead developer: Celularity
Modality: Cell Therapies
Administration: Intravenous

Overview

PDA001, also known as Cenplacel-L, is a preparation of mesenchymal-like cells derived from full-term human placenta. It has immunomodulatory effects and is used in cell therapy. PDA001 has been investigated for its potential in treating multiple sclerosis, Crohn's disease, and other conditions by modulating immune responses and promoting tissue repair.

Brand names: Cenplacel-L
Other names: PDAC cells

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on PDA001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDA001.

Explore the full profile